Global Transarterial Chemoembolization Market

Global Transarterial Chemoembolization Market Size, Share, Growth Analysis, By Product(Hospitals, Ambulatory Surgical Centers), By End-User(Strawberry, apple), By Technology(Lipiodol-based TACE, Drug-Eluting Bead TACE Technology) - Industry Forecast 2024-2031

Report ID: SQMIG35I2318 | Region: Global | Published Date: April, 2024
Pages: 219 | Tables: 92 | Figures: 76

Global Transarterial Chemoembolization Market News

  • In May 2023 Bristol-Myers Squibb is evaluating nivolumab with ipilimumab and nivolumab alone in combination with trans-arterial chemotherapy-embolization (TACE) in participants with intermediate stage liver cancer (CheckMate 74W). 
  • In May 2023, Studies predicted that radiologic patterns play an important role in the outcome of early follow-up intra-arterial chemoembolization in individuals with intermediate-stage hepatocellular carcinoma. 
  • In March 2023, the correlation and effectiveness of Transarterial Chemoembolization (TACE) in mixture with lenvatinib and a PD-1 inhibitor are explored in the treatment of hepatocellular carcinoma (HCC) imparting with portal vein tumor thrombus.
$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Global Transarterial Chemoembolization Market size was valued at USD 16.88 billion in 2022 and is poised to grow from USD 17.81 billion in 2023 to USD 27.33 billion by 2031, growing at a CAGR of 5.5% in the forecast period (2024-2031).

Transarterial chemoembolization market is competitive, comprising both well-established vendors as well as new entrants that lead to dynamism in this industry. The major players in the market are engaging in strategies like new product development, collaboration, and consolidation to increase their dominance. Significant contributions to the competitive dynamics include established medical technology companies specializing in interventional oncology (development of advanced catheters, microcatheters, etc.) as well as embolic agents and drug-eluting bead technologies. 'Boston Scientific Corporation (US)', 'Terumo Corporation (Japan)', 'Cook Medical (US)', 'Cardinal Health (US)', 'Becton, Dickinson and Company (US)', 'Guerbet (France)', 'AngioDynamics, Inc. (US)', 'SIRtex Medical Inc. (Australia)', 'Merit Medical Systems Inc. (US)', 'Varian Medical Systems, Inc. (US)', 'Microvena Therapeutics, Inc. (US)', 'RadioMed LLC (US)', 'IGT Laboratories (US)', 'MicroCath, Inc. (US)', 'Spectranetics, Inc. (US)', 'Penumbra, Inc. (US)', 'Oncotreat SA (Switzerland)', 'Vascular Dynamics, Inc. (US)', 'Shanghai Jahva Medical Co., Ltd. (China)', 'Hangzhou Micro-Tech Co., Ltd. (China)'

The increased incidence of liver cancer worldwide with demands for treatment such as the TACE. Moreover, the ongoing improvements in medical techniques continue to improve the accuracy and efficacy of such treatment processes, leading a doctor and a patient to choose them too. Minimally invasive procedures have also become vital drivers for TACE because it helps patients not experience the pain that comes with traditional treatment methods.

The trend towards the individualized treatment of liver cancer. The health care providers are exploring customised TACE based on patients’ characteristic and general health status including that of their tumour types. The trend supports the larger shift toward precision medicine to maximise the patient’s health outcome. Another major trend in the TACE market is technological innovations. This improves the performance of TACE which is ongoing research work to improve its preciseness and effectiveness. The latest developments in embolic agents, as well as, drug-eluting bead technologies and imaging technologies help target cancerous sites so that therapy can be effective with minimal negative impact to other tissues and body organs.

There was a particular region with high demand in terms of the TACE market, called Asia-Pacific. Countries like China have a high prevalence rate of liver cancer. This trend goes along with increased education, better health facilities, as well as increased spending capacity, hence, making Asia Pacific dominate. The fact that some countries like China and India are investing in health care infrastructure and technology also supports the region’s capacity for TACE.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

Click here right-arrow
logo-images

Related Reports

Global Softgel Capsule Market
Buy Now GET FREE SAMPLE
Lymphoma Treatment Market
Buy Now GET FREE SAMPLE
Global Mineral Supplements Market
Buy Now GET FREE SAMPLE
Pharmaceutical Fine Chemicals Market
Buy Now GET FREE SAMPLE

Feedback From Our Clients

Global Transarterial Chemoembolization Market

Product ID: SQMIG35I2318

$5,300
BUY NOW GET FREE SAMPLE